• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物相关性下颌骨坏死:医学专业人员对骨修饰剂使用和牙科转诊的认知和看法。

Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.

机构信息

Department of Oral Medicine and Radiology, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

出版信息

J Med Life. 2022 Mar;15(3):368-373. doi: 10.25122/jml-2021-0085.

DOI:10.25122/jml-2021-0085
PMID:35449990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9015184/
Abstract

Bone modifying agents (BMA) like bisphosphonates, antiangiogenic, and antiresorptive agents are widely used to manage bone diseases and cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a potentially serious complication seen in patients on BMA therapy. Dental infection is one of the primary risk factors for MRONJ manifestation; hence its complete removal before initiation of BMA is significant. This can be achieved when a medical professional understands MRONJ and its risk factors and implements timely and regular dental referrals. This multicentre study was performed to assess the knowledge about MRONJ and awareness about the implementation of dental referrals among medical professionals. A custom-designed questionnaire tool was designed and validated by a pilot study. 450 practitioners from 6 medical schools and private practitioners in and around the district were surveyed. The results were analyzed using descriptive statistics. 63.5% (n=80) of the respondents prescribed bisphosphonates at a frequency of 0-5 times in a month. However, 62% (n=78) of the practitioners could correctly indicate the most appropriate definition of MRONJ. Only 49.2% (n=62) of them considered dental consultation mandatory. 73% (n=92) of the practitioners were unaware of management guidelines. There exists a significant gap in the knowledge-based applications in the management of MRONJ. Lack of referrals to dentists before BMA therapy can be a pivotal factor in patient morbidity. Practitioners prescribing BMA should advise patients about regular dental visits and monitor for symptoms of MRONJ.

摘要

骨修饰剂(BMA),如双磷酸盐、抗血管生成和抗吸收剂,被广泛用于治疗骨疾病和癌症。药物相关性下颌骨坏死(MRONJ)是 BMA 治疗患者中出现的一种潜在严重并发症。牙科感染是 MRONJ 表现的主要危险因素之一;因此,在开始 BMA 治疗之前彻底清除感染非常重要。当医疗专业人员了解 MRONJ 及其危险因素并及时定期转诊牙科时,就可以实现这一点。这项多中心研究旨在评估医疗专业人员对 MRONJ 的认识和对实施牙科转诊的意识。设计了一个定制的问卷工具,并通过试点研究进行了验证。对来自 6 所医学院和该地区内外的 450 名从业者进行了调查。使用描述性统计方法分析结果。63.5%(n=80)的受访者每月开具双磷酸盐的频率为 0-5 次。然而,62%(n=78)的从业者能够正确指出 MRONJ 的最恰当定义。只有 49.2%(n=62)的人认为牙科咨询是强制性的。73%(n=92)的从业者不知道管理指南。在 MRONJ 管理的基于知识的应用方面存在显著差距。在开始 BMA 治疗之前未向牙医转诊可能是患者发病率的关键因素。开具 BMA 的从业者应告知患者定期看牙医,并监测 MRONJ 的症状。

相似文献

1
Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.药物相关性下颌骨坏死:医学专业人员对骨修饰剂使用和牙科转诊的认知和看法。
J Med Life. 2022 Mar;15(3):368-373. doi: 10.25122/jml-2021-0085.
2
The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.在转移性乳腺癌和前列腺癌患者中使用骨修饰剂后进行口腔检查的趋势和口腔并发症的发生率:来自韩国国家健康保险服务的数据分析。
BMC Health Serv Res. 2024 Apr 2;24(1):412. doi: 10.1186/s12913-024-10859-7.
3
How we manage medication-related osteonecrosis of the jaw.我们如何管理药物相关性颌骨坏死。
Eur J Med Res. 2024 Aug 2;29(1):402. doi: 10.1186/s40001-024-01912-6.
4
Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.药物相关性颌骨坏死:癌症和骨转移患者的预防、诊断和管理。
Cancer Treat Rev. 2018 Sep;69:177-187. doi: 10.1016/j.ctrv.2018.06.007. Epub 2018 Jun 18.
5
MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw.MASCC/ISOO 临床实践声明:原发性乳腺癌患者的辅助骨修饰剂 - 预防与药物相关的颌骨坏死。
Support Care Cancer. 2024 Jul 25;32(8):547. doi: 10.1007/s00520-024-08687-w.
6
Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study.牙科专业人员对药物相关性颌骨坏死的认知:一项多中心研究。
Oral Health Prev Dent. 2020 Jul 4;18(3):505-509. doi: 10.3290/j.ohpd.a43361.
7
Does inflammatory dental disease affect the development of medication-related osteonecrosis of the jaw in patients using high-dose bone-modifying agents?炎症性牙科疾病是否会影响使用大剂量骨改良药物的患者发生药物相关性颌骨坏死的发展?
Clin Oral Investig. 2021 May;25(5):3087-3093. doi: 10.1007/s00784-020-03632-7. Epub 2020 Oct 14.
8
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
9
Medical and Dental Professions' Varying Levels of Awareness Regarding Medication-related Osteonecrosis of the Jaw in Saudi Arabia? A Cross-sectional Study.沙特阿拉伯医学和牙科专业人员对药物相关性颌骨坏死的认知程度存在差异吗?一项横断面研究。
J Contemp Dent Pract. 2024 Jan 1;25(1):62-67. doi: 10.5005/jp-journals-10024-3622.
10
Awareness and Attitude among Physicians Regarding Bisphosphonaterelated Osteonecrosis of the Jaw (BRONJ): A Cross-sectional Study.医师对双膦酸盐相关性颌骨骨坏死(BRONJ)的认知和态度:一项横断面研究。
Curr Drug Saf. 2023;18(3):361-367. doi: 10.2174/1574886317666220514160507.

引用本文的文献

1
Pathogenesis of Medication-Related Osteonecrosis of the Jaw: Odontogenic Infection-Preceding Type and Osteonecrosis-Preceding Type.药物相关性颌骨坏死的发病机制:牙源性感染先发型和骨坏死先发型。
Cureus. 2024 May 13;16(5):e60223. doi: 10.7759/cureus.60223. eCollection 2024 May.
2
Physicians' awareness of medication-related osteonecrosis of the jaw in patients with osteoporosis.医生对骨质疏松症患者颌骨药物相关性坏死的认知。
PLoS One. 2024 Jan 26;19(1):e0297500. doi: 10.1371/journal.pone.0297500. eCollection 2024.
3
Awareness, perceptions and attitudes toward medication-related osteonecrosis of the jaw among physicians who treat osteoporosis.治疗骨质疏松症的医生对药物相关性颌骨坏死的认知、看法和态度
Saudi Pharm J. 2023 Sep;31(9):101707. doi: 10.1016/j.jsps.2023.101707. Epub 2023 Jul 23.
4
Dentists' Awareness of Medication-Related Osteonecrosis of the Jaw (Risk Factors, Drugs, and Prevention) in the Republic of Croatia.克罗地亚共和国牙医对药物相关性颌骨坏死(风险因素、药物及预防)的认知
Acta Stomatol Croat. 2023 Jun;57(2):121-132. doi: 10.15644/asc57/2/3.

本文引用的文献

1
Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches.治疗药物相关性颌骨坏死(MRONJ)的各种治疗方法及其局限性:关于新的分子和细胞治疗方法的叙述性综述
Antioxidants (Basel). 2021 Apr 27;10(5):680. doi: 10.3390/antiox10050680.
2
Dentists' knowledge about medication-related osteonecrosis of the jaw and its management.牙医对药物性颌骨坏死及其治疗的了解。
Heliyon. 2020 Jul 27;6(7):e04321. doi: 10.1016/j.heliyon.2020.e04321. eCollection 2020 Jul.
3
Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.预防、识别和管理药物相关性颌骨坏死:护士和其他相关医疗保健专业人员的实用指南。
Support Care Cancer. 2020 Sep;28(9):4019-4029. doi: 10.1007/s00520-020-05440-x. Epub 2020 Apr 19.
4
Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study.牙科专业人员对药物相关性颌骨坏死的认知:一项多中心研究。
Oral Health Prev Dent. 2020 Jul 4;18(3):505-509. doi: 10.3290/j.ohpd.a43361.
5
Perceptions and attitudes of patients towards medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in England.患者对药物相关性颌骨坏死 (MRONJ)的认知和态度:英格兰的一项定性研究。
BMJ Open. 2019 Mar 3;9(3):e024376. doi: 10.1136/bmjopen-2018-024376.
6
Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.药物相关性颌骨坏死:预防、诊断和治疗的定义及最佳实践。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008. Epub 2018 Oct 9.
7
Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.药物相关性颌骨坏死的阶段特异性治疗策略:药物混悬液方案的系统评价和荟萃分析。
Clin Oral Investig. 2018 Mar;22(2):597-615. doi: 10.1007/s00784-017-2325-6. Epub 2018 Jan 13.
8
Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw.医生对双膦酸盐相关颌骨坏死的认知
BMC Oral Health. 2016 Sep 7;16(1):92. doi: 10.1186/s12903-016-0290-0.
9
Oncologists awareness about bisphosphonate related osteonecrosis of the jaws.肿瘤学家对双膦酸盐相关颌骨坏死的认知。
J Pak Med Assoc. 2016 Jul;66(7):880-3.
10
Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates.安大略省牙医在治疗接受双膦酸盐治疗的患者时的知识、实践和观点。
J Oral Maxillofac Surg. 2015 Jun;73(6):1095-105. doi: 10.1016/j.joms.2014.12.040. Epub 2015 Jan 12.